- Home
- EXAS vs KEP Comparison
EXAS vs KEP Comparison
Compare EXAS & KEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- KEP
- Stock Information
- Founded
- EXAS 1995
- KEP 1961
- Country
- EXAS United States
- KEP South Korea
- Employees
- EXAS N/A
- KEP N/A
- Industry
- EXAS Medical Specialities
- KEP Electric Utilities: Central
- Sector
- EXAS Health Care
- KEP Utilities
- Exchange
- EXAS Nasdaq
- KEP Nasdaq
- Market Cap
- EXAS 12.3B
- KEP 9.4B
- IPO Year
- EXAS N/A
- KEP N/A
- Fundamental
- Price
- EXAS $69.23
- KEP $7.52
- Analyst Decision
- EXAS Strong Buy
- KEP
- Analyst Count
- EXAS 13
- KEP 0
- Target Price
- EXAS $77.18
- KEP N/A
- AVG Volume (30 Days)
- EXAS 1.8M
- KEP 118.6K
- Earning Date
- EXAS 11-05-2024
- KEP 10-29-2024
- Dividend Yield
- EXAS N/A
- KEP N/A
- EPS Growth
- EXAS N/A
- KEP N/A
- EPS
- EXAS N/A
- KEP 3.00
- Revenue
- EXAS $2,612,011,000.00
- KEP $65,870,350,762.00
- Revenue This Year
- EXAS $15.53
- KEP $5.29
- Revenue Next Year
- EXAS $13.78
- KEP $2.91
- P/E Ratio
- EXAS N/A
- KEP $5.05
- Revenue Growth
- EXAS 13.54
- KEP 12.78
- 52 Week Low
- EXAS $40.62
- KEP $5.93
- 52 Week High
- EXAS $79.62
- KEP $9.55
- Technical
- Relative Strength Index (RSI)
- EXAS 56.31
- KEP 47.01
- Support Level
- EXAS $69.31
- KEP $7.30
- Resistance Level
- EXAS $71.50
- KEP $7.62
- Average True Range (ATR)
- EXAS 2.02
- KEP 0.08
- MACD
- EXAS -0.22
- KEP -0.00
- Stochastic Oscillator
- EXAS 64.53
- KEP 40.30
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment.